Health
STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more
Publication: STAT
Author: Ed Silverman
Source published: 18/11/2026, 14:26:04 UTC
Briefing created: 19/11/2026, 08:15:40 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 19/11/2026, 08:06:25 UTC.
Briefings
The Trump administration withdrew Heidi Overton's nomination to lead the U.S. Food and Drug Administration due to Senate committee concerns about her vaccine policy stance. Simultaneously, Merck halted development of its experimental blood cancer drug nemtabrutinib after an independent monitoring committee determined the benefits did not outweigh the risks based on late-stage study data.
Key points
- The Trump administration withdrew Heidi Overton's nomination to lead the U.S. Food and Drug Administration over concerns regarding her support for scaling back vaccine recommendations.
- Merck plans to stop development of its experimental blood cancer drug nemtabrutinib after an independent monitoring committee concluded the benefits may not outweigh the risks.
Context
This briefing covers a political setback for the Trump administration's FDA nomination and a pharmaceutical development halt involving Merck's nemtabrutinib. The withdrawal stems from Senate committee reservations about Overton's preventive care and policy positions.
Limitations
Evidence is limited to reported news sources; specific vote counts, committee vote dates, and Merck's exact timeline for the drug halt are not provided. The study data referenced is described as late-stage, and the independent monitoring committee's specific methodology is not detailed.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 19/11/2026, 08:15:40 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeia4h6ikopfno4tyepagd54abyvf27l5t6kuv6uwafi5cwx3qnidre